New EU products in 2014: two firsts, nine novel anticancers, and a troupe of orphans
This article was originally published in SRA
Executive Summary
Thirty-four new active substances/biologics were among the 80-odd products approved for marketing by the European Commission in 2014, many of them for rare or difficult to treat diseases1,2. Ten of the new products were biologics, the remainder being new chemical entities.